User menu

Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data.

Primary tabs
Add to cart
Print
Copyright (Sherpa/Romeo)
Authors :
Document type : Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection
Publication date : 2006
Language : Anglais
Conference : "42nd Annual Meeting of the American-Society-of-Clinical-Oncology", Atlanta (Ga) (Jun 02-06, 2006)
Journal information : "Journal of Clinical Oncology" - Vol. 24, no. 18, p. 159S-159S (2006)
Peer reviewed : yes
issn : 0732-183X
e-issn : 1527-7755
Publisher : Amer Soc Clinical Oncology (Alexandria)
Affiliations : UCL - Cliniques universitaires Saint-Luc
UCL - MD/MINT - Département de médecine interne
UCL - AGRO/CABI - Département de chimie appliquée et des bio-industries
Links :
Bibliographic reference Tejpar, Sabine ; Humblet, Yves ; Peeters, Marie-Rose ; Gelderblom, H. ; Vermorken, J. ; et. al. Dose-escalation study using up to twice the standard dose of cetuximab in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST study): Preliminary data..42nd Annual Meeting of the American-Society-of-Clinical-Oncology (Atlanta (Ga), Jun 02-06, 2006). In: Journal of Clinical Oncology, Vol. 24, no. 18, p. 159S-159S (2006)
Permanent URL http://hdl.handle.net/2078.1/59894